Mutational landscape and clonal diversity of pulmonary adenoid cystic carcinoma

References

• Bell D, Hanna EY. Salivary gland cancers: biology and molecular targets for therapy. Curr Oncol Rep. 2012;14(2):166–174. doi:10.1007/s11912-012-0220-5.
   PubMed Web of Science ®Google Scholar
• Gondivkar SM, Gadbail AR, Chole R, Parikh RV. Adenoid cystic carcinoma: a rare clinical entity and literature review. Oral Oncol. 2011;47(4):231–236. doi:10.1016/j.oraloncology.2011.01.009.
   PubMed Web of Science ®Google Scholar
• Zhu F, Liu Z, Hou Y, He D, Ge X, Bai C, Jiang L, Li S. Primary salivary gland-type lung cancer: clinicopathological analysis of 88 cases from China. J Thorac Oncol. 2013;8(12):1578–1584. doi:10.1097/JTO.0b013e3182a7d272.
   PubMed Web of Science ®Google Scholar
• Roden AC, Greipp PT, Knutson DL, Kloft-Nelson SM, Jenkins SM, Marks RS, Aubry MC, García JJ. Histopathologic and cytogenetic features of pulmonary adenoid cystic carcinoma. J Thorac Oncol. 2015;10(11):1570–1575. doi:10.1097/JTO.0000000000000656.
   PubMed Web of Science ®Google Scholar
• Molina JR, Aubry MC, Lewis JE, Wampfler JA, Williams BA, Midthun DE, Yang P, Cassivi SD. Primary salivary gland-type lung cancer: spectrum of clinical presentation, histopathologic and prognostic factors. Cancer. 2007;110(10):2253–2259. doi:10.1002/cncr.23048.
   PubMed Web of Science ®Google Scholar
• Hu MM, Hu Y, He JB, Li BL. Primary adenoid cystic carcinoma of the lung: clinicopathological features, treatment and results. Oncol Lett. 2015;9(3):1475–1481. doi:10.3892/ol.2015.2859.
   PubMed Web of Science ®Google Scholar
• Qing S, Zhou K, Liu X, Li X, Deng F, Ma Y. Primary pulmonary adenoid cystic carcinoma: clinicopathological analyses of 12 cases. Int J Clin Exp Pathol. 2015;8(6):7619–7626.
   PubMed Web of Science ®Google Scholar
• Pandey D, Garg PK, Jakhetiya A, Pandey R, Bhoriwal S, Nath D, Kumar S. Surgical experience of primary salivary gland tumors of lung: A case series. Int J Surg. 2015;21:92–96. doi:10.1016/j.ijsu.2015.06.084.
   PubMed Web of Science ®Google Scholar
• Bennett AK, Mills SE, Wick MR. Salivary-type neoplasms of the breast and lung. Semin Diagn Pathol. 2003;20(4):279–304.
   PubMed Web of Science ®Google Scholar
• Kanematsu T, Yohena T, Uehara T, Ushijima C, Asoh H, Yoshino I, Ichinose Y. Treatment outcome of resected and nonresected primary adenoid cystic carcinoma of the lung. Ann Thorac Cardiovasc Surg. 2002;8(2):74–77.
   PubMedGoogle Scholar
• Dodd RL, Slevin NJ. Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies. Oral Oncol. 2006;42(8):759–769. doi:10.1016/j.oraloncology.2006.01.001.
   PubMed Web of Science ®Google Scholar
• Song Z, Wu W, Zhang Y. Effective treatment with icotinib in primary adenoid cystic carcinoma of the lung with liver metastasis. J Thorac Oncol. 2014;9(9):e67–69. doi:10.1097/JTO.0000000000000247.
   PubMed Web of Science ®Google Scholar
• Liu J, Hau E, Links M, Graham PH. Adenoid cystic carcinoma of the lung: response to tamoxifen after chemoradiation. Asia Pac J Clin Oncol. 2016;12(2):e352–e355. doi:10.1111/ajco.12184.
   PubMed Web of Science ®Google Scholar
• Shadaba A, Gaze MN, Grant HR. The response of adenoid cystic carcinoma to tamoxifen. J Laryngol Otol. 1997;111(12):1186–1189.
   PubMed Web of Science ®Google Scholar
• Kang DY, Yoon YS, Kim HK, Choi YS, Kim K, Shim YM, Kim J. Primary salivary gland-type lung cancer: surgical outcomes. Lung Cancer. 2011;72(2):250–254. doi:10.1016/j.lungcan.2010.08.021.
   PubMed Web of Science ®Google Scholar
• Macarenco RS, Uphoff TS, Gilmer HF, Jenkins RB, Thibodeau SN, Lewis JE, Molina JR, Yang P, Aubry M-C. Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study. Mod Pathol. 2008;21(9):1168–1175. doi:10.1038/modpathol.2008.113.
   PubMed Web of Science ®Google Scholar
• Aubry MC, Heinrich MC, Molina J, Lewis JE, Yang P, Cassivi SD, Corless CL. Primary adenoid cystic carcinoma of the lung: absence of KIT mutations. Cancer. 2007;110(11):2507–2510. doi:10.1002/cncr.23075.
   PubMed Web of Science ®Google Scholar
• Huo Z, Wu H, Li S, Liang Z. Molecular genetic studies on EGFR, KRAS, BRAF, ALK, PIK3CA, PDGFRA, and DDR2 in primary pulmonary adenoid cystic carcinoma. Diagn Pathol. 2015;10:161. doi:10.1186/s13000-015-0409-7.
   PubMed Web of Science ®Google Scholar
• Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, Cook K, Stepansky A, Levy D, Esposito D, et al. Tumour evolution inferred by single-cell sequencing. Nature. 2011;472(7341):90–94. doi:10.1038/nature09807.
   PubMed Web of Science ®Google Scholar
• Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486(7403):395–399. doi:10.1038/nature10933.
   PubMed Web of Science ®Google Scholar
• Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R, Rosenthal R, et al. Tracking the evolution of non-small-cell lung cancer. N Engl J Med. 2017;376(22):2109–2121. doi:10.1056/NEJMoa1616288.
   PubMed Web of Science ®Google Scholar
• Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, Seth S, Chow CW, Cao Y, Gumbs C, et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science. 2014;346(6206):256–259. doi:10.1126/science.1256930.
   PubMed Web of Science ®Google Scholar
• Anderson K, Lutz C, Van Delft FW, Bateman CM, Guo Y, Colman SM, Kempski H, Moorman AV, Titley I, Swansbury J, et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature. 2011;469(7330):356–361. doi:10.1038/nature09650.
   PubMed Web of Science ®Google Scholar
• Gervais C, Murati A, Helias C, Struski S, Eischen A, Lippert E, Tigaud I, Penther D, Bastard C, Mugneret F, et al. Acute myeloid leukaemia with 8p11 (MYST3) rearrangement: an integrated cytologic, cytogenetic and molecular study by the groupe francophone de cytogenetique hematologique. Leukemia. 2008;22(8):1567–1575. doi:10.1038/leu.2008.128.
   PubMed Web of Science ®Google Scholar
• Dawson MA. The cancer epigenome: concepts, challenges, and therapeutic opportunities. Science. 2017;355(6330):1147–1152. doi:10.1126/science.aam7304.
   PubMed Web of Science ®Google Scholar
• Mitani Y, Li J, Rao PH, Zhao Y-J, Bell D, Lippman SM, Weber RS, Caulin C, El-Naggar AK. Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: incidence, variability, and clinicopathologic significance. Clin Cancer Res. 2010;16(19):4722–4731. doi:10.1158/1078-0432.CCR-10-0463.
   PubMed Web of Science ®Google Scholar
• Mitani Y, Rao PH, Futreal PA, Roberts DB, Stephens PJ, Zhao Y-J, Zhang L, Mitani M, Weber RS, Lippman SM, et al. Novel chromosomal rearrangements and break points at the t(6;9) in salivary adenoid cystic carcinoma: association with MYB-NFIB chimeric fusion, MYB expression, and clinical outcome. Clin Cancer Res. 2011;17(22):7003–7014. doi:10.1158/1078-0432.CCR-11-1870.
   PubMed Web of Science ®Google Scholar
• Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998–2006. doi:10.1001/jama.2014.3741.
   PubMed Web of Science ®Google Scholar
• Xia N. An J, Jiang QQ, Li M, Tan J, Hu CP. Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients. Exp Lung Res. 2013;39(8):328–335. doi:10.3109/01902148.2013.819535.
   Google Scholar
• Lu RL, Hu CP, Yang HP, Li YY, Gu QH, Wu L. Biological characteristics and epidermal growth factor receptor tyrosine kinase inhibitors efficacy of EGFR mutation and its subtypes in lung adenocarcinoma. Pathol Oncol Res. 2014;20(2):445–451. doi:10.1007/s12253-013-9715-0.
   Google Scholar
• Xiao D, Lu C, Zhu W, He Q, Li Y, Fu C, Zhou J, Liu S, Tao Y. Comparison of small biopsy specimens and surgical specimens for the detection of EGFR mutations and EML4-ALK in non-small-cell lung cancer. Oncotarget. 2016;7(37):59049–59057. doi:10.18632/oncotarget.10011.
   Google Scholar
• Ge L, Shi R. Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer. Int J Clin Exp Med. 2015Jul 15;8(7):10330–10339.
   Google Scholar
• Tan L, Hu Y, Tao Y, Wang B, Xiao J, Tang Z, Lu T, Tang H. Expression and copy number gains of the RET gene in 631 early and mid stage non-small cell lung cancer cases. Thorac Cancer. 2018 [Epub ahead of print]. doi:10.1111/1759-7714.12603.
   Google Scholar
• Issa JP. Aging and epigenetic drift: a vicious cycle. J Clin Invest. 2014;124(1):24–29. doi:10.1172/JCI69735.
   Google Scholar